Advent International enters agreements to buy Zentiva from Sanofi for €1.9bn; deal closes
Sanofi confirmed that is in exclusive negotiations to divest its European generics business Zentiva BV to private equity firm Advent International for €1.9bn ($2.3bn). The deal is said to be binding and fully financed, and could close by the end of year, pending definitive agreements and regulatory approval.
- Generic Drugs
- OTC, Consumer
- Full Acquisition
- Payment Includes Cash
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.